JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grewal, R. S.
Right arrow Articles by David, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grewal, R. S.
Right arrow Articles by David, J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 160, Issue 2, 268-276, 1968
Copyright © 1968 by American Society for Pharmacology and Experimental Therapeutics


PHARMACOLOGY OF Go-1002

R. S. Grewal 1, C. L. Kaul 1, and J. David 1

1 CIBA Research Centre, Goregaon, Bombay 63, India

Go-1002 (1-(5-methyl-1-phenyl-4-pyrazole-3-[4-(o-tolyl)-1-piperazinyl]-1-propanone hydrochloride) is a potent orally active hypotensive agent, with epinephrine-, amphetamine- and tyramine-blocking properties. It produces marked antihypertensive effects in renal hypertensive rats. It produces diminution of peripheral resistance by causing vasodilatation. This has been demonstrated in the isolated perfused hind limb and by measuring femoral artery blood flow. Its vasodilator action is seen in coronary vessels as well. It blocks centrally mediated vasomotor reflexes such as the carotid sinus occlusion reflex and the pressor response to stimulation of the central end of the vagus nerve. The vasopressor response elicited by stimulation of the posterior hypothalamus and reticular formation is markedly reduced by intraarterial injection of this compound. It produces a depletion of catecholamines from the heart, brain and adrenals. It does not possess any ganglionic blocking activity. It has central sedative tranquilizing properties and shows marked antiaggressive activity in rhesus monkeys.

Submitted on July 6, 1967
Accepted on December 8, 1967







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics.